Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Grieve S, Wajnberg G, Lees M, Chacko S, Weir J, Crapoulet N, Reiman T.

Blood Adv. 2019 Nov 26;3(22):3613-3625. doi: 10.1182/bloodadvances.2019000374.

PMID:
31743393
2.

Large painful lactating adenomas effectively treated during pregnancy with bromocriptine.

Mendez MA, Jones KM, Reiman TR, Kremer HL, Ahmadiyeh N.

Breast J. 2019 Sep;25(5):974-976. doi: 10.1111/tbj.13380. Epub 2019 Jun 4.

PMID:
31165510
3.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE.

Leuk Lymphoma. 2019 Apr;60(4):912-919. doi: 10.1080/10428194.2018.1515937. Epub 2018 Oct 10.

PMID:
30301414
4.

Making It Happen: Middle Managers' Roles in Innovation Implementation in Health Care.

Urquhart R, Kendell C, Folkes A, Reiman T, Grunfeld E, Porter GA.

Worldviews Evid Based Nurs. 2018 Dec;15(6):414-423. doi: 10.1111/wvn.12324. Epub 2018 Oct 6.

5.

Factors influencing middle managers' commitment to the implementation of innovations in cancer care.

Urquhart R, Kendell C, Folkes A, Reiman T, Grunfeld E, Porter G.

J Health Serv Res Policy. 2019 Apr;24(2):91-99. doi: 10.1177/1355819618804842. Epub 2018 Oct 5.

PMID:
30290703
6.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.

Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE.

Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15.

PMID:
28504033
7.

Clinician participation in CADTH's pan-Canadian Oncology Drug Review: contribution and impact on cancer drug funding recommendations.

Trudeau M, Hoskins P, Reiman T, Chambers A, Mai H, Wheatley-Price P.

Curr Oncol. 2017 Apr;24(2):71-74. doi: 10.3747/co.24.3644. Epub 2017 Apr 27. No abstract available.

8.

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T.

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. No abstract available.

PMID:
27338095
9.

A simple prognostic model for overall survival in metastatic renal cell carcinoma.

Assi HI, Patenaude F, Toumishey E, Ross L, Abdelsalam M, Reiman T.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):113-9. doi: 10.5489/cuaj.3351.

10.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG.

Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29. Review.

PMID:
26710887
11.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T.

Leuk Lymphoma. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15. No abstract available.

PMID:
26376958
12.

Effects of supervised exercise on progression-free survival in lymphoma patients: an exploratory follow-up of the HELP Trial.

Courneya KS, Friedenreich CM, Franco-Villalobos C, Crawford JJ, Chua N, Basi S, Norris MK, Reiman T.

Cancer Causes Control. 2015 Feb;26(2):269-276. doi: 10.1007/s10552-014-0508-x. Epub 2014 Dec 10.

PMID:
25491935
13.

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T.

Cancer. 2015 Mar 1;121(5):716-23. doi: 10.1002/cncr.29103. Epub 2014 Oct 29.

14.

Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.

Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, Thomas C, Tonelli M.

PLoS One. 2014 Jul 2;9(7):e101145. doi: 10.1371/journal.pone.0101145. eCollection 2014. Review.

15.

Researchers' Roles in Patient Safety Improvement.

Pietikäinen E, Reiman T, Heikkilä J, Macchi L.

J Patient Saf. 2016 Mar;12(1):25-33. doi: 10.1097/PTS.0000000000000096.

PMID:
24618644
16.

Does the concept of safety culture help or hinder systems thinking in safety?

Reiman T, Rollenhagen C.

Accid Anal Prev. 2014 Jul;68:5-15. doi: 10.1016/j.aap.2013.10.033. Epub 2013 Nov 7.

PMID:
24275532
17.

The validity of the Nordic patient safety culture questionnaire (TUKU).

Reiman T, Silla I, Pietikäinen E.

Int J Risk Saf Med. 2013;25(3):169-84. doi: 10.3233/JRS-130595.

PMID:
24047688
18.

Patient satisfaction with participation in a randomized exercise trial: effects of randomization and a usual care posttrial exercise program.

Courneya KS, Forbes CC, Trinh L, Sellar CM, Friedenreich CM, Reiman T.

Clin Trials. 2013;10(6):959-66. doi: 10.1177/1740774513495985. Epub 2013 Aug 5.

PMID:
23918843
19.

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD.

J Clin Oncol. 2013 Jun 20;31(18):2347-57. doi: 10.1200/JCO.2012.47.7901. Epub 2013 May 20.

20.

Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE.

J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.

PMID:
23530101
21.

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.

Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM.

Blood. 2013 Feb 28;121(9):1517-23. doi: 10.1182/blood-2012-09-451872. Epub 2013 Jan 7.

22.

Dietary patterns of patients with advanced lung or colorectal cancer.

Prado CM, Lieffers JR, Bergsten G, Mourtzakis M, Baracos VE, Reiman T, Sawyer MB, McCargar LJ.

Can J Diet Pract Res. 2012 Winter;73(4):e298-303.

PMID:
23217447
23.

Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.

White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S.

Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.

PMID:
23141150
24.

In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Thulien KJ, Belch AR, Reiman T, Pilarski LM.

Mol Cancer. 2012 Oct 19;11:78. doi: 10.1186/1476-4598-11-78.

25.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. doi: 10.1016/j.clml.2012.08.003.

PMID:
23040437
26.

A randomized trial of aerobic exercise and sleep quality in lymphoma patients receiving chemotherapy or no treatments.

Courneya KS, Sellar CM, Trinh L, Forbes CC, Stevinson C, McNeely ML, Peddle-McIntyre CJ, Friedenreich CM, Reiman T.

Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):887-94. doi: 10.1158/1055-9965.EPI-12-0075. Epub 2012 Apr 20.

27.

System modeling with the DISC framework: evidence from safety-critical domains.

Reiman T, Pietikäinen E, Oedewald P, Gotcheva N.

Work. 2012;41 Suppl 1:3018-25. doi: 10.3233/WOR-2012-0558-3018.

PMID:
22317179
28.

Competing values, tensions and trade-offs in management of nuclear power plants.

Reiman T, Rollenhagen C.

Work. 2012;41 Suppl 1:722-9. doi: 10.3233/WOR-2012-0232-722.

PMID:
22316807
29.

Aberrations in plasma phospholipid fatty acids in lung cancer patients.

Murphy RA, Bureyko TF, Mourtzakis M, Chu QS, Clandinin MT, Reiman T, Mazurak VC.

Lipids. 2012 Apr;47(4):363-9. doi: 10.1007/s11745-011-3641-2. Epub 2011 Dec 10.

PMID:
22160451
30.

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.

Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L.

J Thorac Oncol. 2011 Nov;6(11):1950-4. doi: 10.1097/JTO.0b013e3182333df5.

31.

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

Evans RP, Dueck G, Sidhu R, Ghosh S, Toman I, Loree J, Bahlis N, Klimowicz AC, Fung J, Jung M, Lai R, Pilarski LM, Belch AR, Reiman T.

Leuk Res. 2011 Dec;35(12):1637-43. doi: 10.1016/j.leukres.2011.07.016. Epub 2011 Aug 3.

PMID:
21816470
32.

Effects of supervised exercise on motivational outcomes and longer-term behavior.

Courneya KS, Stevinson C, McNeely ML, Sellar CM, Friedenreich CM, Peddle-McIntyre CJ, Chua N, Reiman T.

Med Sci Sports Exerc. 2012 Mar;44(3):542-9. doi: 10.1249/MSS.0b013e3182301e06. Review.

PMID:
21814149
33.

Predictors of follow-up exercise behavior 6 months after a randomized trial of supervised exercise training in lymphoma patients.

Courneya KS, Stevinson C, McNeely ML, Sellar CM, Friedenreich CM, Peddle-McIntyre CJ, Chua N, Reiman T.

Psychooncology. 2012 Oct;21(10):1124-31. doi: 10.1002/pon.2010. Epub 2011 Jul 18.

PMID:
21766483
34.

A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.

Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, Melosky B, Reiman T, Romeo P, Shepherd FA, Tsao MS, Leighl NB.

J Thorac Oncol. 2011 Aug;6(8):1379-91. doi: 10.1097/JTO.0b013e318220cb8e. Review.

35.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P; LACE-Bio Group.

Ann Oncol. 2012 Jan;23(1):86-93. doi: 10.1093/annonc/mdr033. Epub 2011 Apr 6.

36.

Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics.

Toman I, Loree J, Klimowicz AC, Bahlis N, Lai R, Belch A, Pilarski L, Reiman T.

Leuk Lymphoma. 2011 Apr;52(4):659-67. doi: 10.3109/10428194.2010.548535. Epub 2011 Jan 11.

PMID:
21438833
37.

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy.

Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC.

Cancer. 2011 Apr 15;117(8):1775-82. doi: 10.1002/cncr.25709. Epub 2011 Feb 28.

38.

Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.

Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC.

Cancer. 2011 Aug 15;117(16):3774-80. doi: 10.1002/cncr.25933. Epub 2011 Feb 15.

39.

Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.

Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.

J Thorac Oncol. 2011 Feb;6(2):384-6. doi: 10.1097/JTO.0b013e318200e509.

40.

Multilayered approach to patient safety culture.

Reiman T, Pietikäinen E, Oedewald P.

Qual Saf Health Care. 2010 Oct;19(5):e20. doi: 10.1136/qshc.2008.029793. Epub 2010 Aug 19.

PMID:
20724396
41.

Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients.

Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC.

J Nutr. 2010 Sep;140(9):1602-6. doi: 10.3945/jn.110.123521. Epub 2010 Jul 14.

PMID:
20631325
42.

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.

Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T.

Cancer. 2010 Oct 1;116(19):4541-8. doi: 10.1002/cncr.25377.

43.

Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.

Klarenbach S, Manns B, Reiman T, Reaume MN, Lee H, Lloyd A, Wiebe N, Hemmelgarn B, Tonelli M.

Cancer. 2010 Jul 1;116(13):3224-32. doi: 10.1002/cncr.25052.

44.

Predictors of adherence to supervised exercise in lymphoma patients participating in a randomized controlled trial.

Courneya KS, Stevinson C, McNeely ML, Sellar CM, Peddle CJ, Friedenreich CM, Mazurek A, Chua N, Tankel K, Basi S, Reiman T.

Ann Behav Med. 2010 Aug;40(1):30-9. doi: 10.1007/s12160-010-9205-5.

PMID:
20563764
45.

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.

Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB.

Cancer Chemother Pharmacol. 2011 Jan;67(1):93-101. doi: 10.1007/s00280-010-1288-y. Epub 2010 Mar 5.

PMID:
20204364
46.

Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.

Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S.

Am J Clin Nutr. 2010 Apr;91(4):1133S-1137S. doi: 10.3945/ajcn.2010.28608C. Epub 2010 Feb 17.

PMID:
20164322
47.

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.

Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F.

Bone Marrow Transplant. 2010 Aug;45(8):1316-24. doi: 10.1038/bmt.2009.335. Epub 2009 Dec 7.

PMID:
19966851
48.

The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.

Sève P, Reiman T, Dumontet C.

Lung Cancer. 2010 Feb;67(2):136-43. doi: 10.1016/j.lungcan.2009.09.007. Epub 2009 Oct 13. Review.

PMID:
19828208
49.

Moderator effects in a randomized controlled trial of exercise training in lymphoma patients.

Courneya KS, Sellar CM, Stevinson C, McNeely ML, Friedenreich CM, Peddle CJ, Basi S, Chua N, Tankel K, Mazurek A, Reiman T.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2600-7. doi: 10.1158/1055-9965.EPI-09-0504.

50.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2009 Dec;23(12):2210-21. doi: 10.1038/leu.2009.174. Epub 2009 Oct 1. Review.

Supplemental Content

Loading ...
Support Center